If I was betting the future on genetics, I might hold on to my money til it gets extremely cheap to do full exome sequencing and medical records aggregation.
There’s probably going to be 20-40 companies doing both of these things. (Full exome sequencing and medical records aggregation).
In the interim, I’d focus on methodologies that revolve around collecting the attention and/or spit of sick people, twins, triplets, and quadruplets for as low as a cost as possible.
Blood generally presents issues, spit works better, or at least according to the molecular biologists I’ve spoken to.
Read the latest blog post on marketing, the macro, and tech.